ClinicalTrials.gg
RecruitingNCT04414878Updated Jun 4, 2020

VitaFlow™ II Transcatheter Aortic Valve System Pre-market Trial

An interventional study of VitaFlow™ II Transcatheter Aortic Valve System in Aortic Stenosis, sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Recruiting at 4 sites in China. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2022, 4 years 9 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 3 months after the study started (first participant enrolled Jan 2018, registered May 2020).
  • Started Jan 2018; still recruiting 8 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
18th of 47
145 · median 120
Started
2018
with 3 others
No phase
37 of 69
20 open now
Primary completion
2022-01
later than 5 of 50 live
Registered
15th of 69
by date
Lead sponsor
6 of 69
Shanghai MicroPort CardioFlow Medtech Co., Ltd.

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 18th largest by planned enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2018, is one of 37 with no phase, reaches primary completion later than 5 of the 50 other live ones, and was the 15th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness of Microport™ CardioFlow VitaFlow™ II Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.

Read the detailed description

This a prospective, multi-center, single-arm, objective performance clinical investigation, aiming to evaluate the safety and effectiveness of Microport™ CardioFlow VitaFlow™ II Transcatheter Aortic Valve System for the treatment of severe aortic stenosis. A total of 145 subjects will be enrolled in 18 clinical centers within China. Clinical or telephone follow-up is scheduled at 30 days, 6 months, 12 months, and 2-5 years after valve implantation.

03

Conditions studied

  • Aortic Stenosis
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥70 years;
  2. Symptomatic , severe, aortic valve stenosis : peak velocity ≥4.0m/s, or mean transvalvular gradient ≥40mmHg(1 mmHg=0.133kPa), or effective orifice area\<0.8cm² (or EOA index\<0.5cm²/m²);
  3. ≥II class;
  4. Estimated life-expectancy>12 months after implantation of the prosthetic valve;
  5. Anatomically suitable for the transcatheter aortic valve implantation procedure;
  6. The patients considered to high-risk or not suitable for surgical aortic valve replacement (SAVR), as assessed by two or above heart surgeons; The patient has been informed of the nature of the study, is willing to enroll in the study by signing a patient and agreeing to the scheduled follow up requirement.

Exclusion criteria

Exclusion Criteria:

  1. Acute myocardial infarction (MI) in last 30 days before the treatment;
  2. Aortic root anatomy not suitable for the implantation of the transcatheter aortic valve;
  3. Complicated lesion of the aortic valve (aortic stenosis with severe regurgitation); moderate-severe mitral valve stenosis; severe mitral valve regurgitation; severe tricuspid valve regurgitation;
  4. Previous implantation of heart valve at any position;
  5. Hemodynamic instability requiring mechanical hemodynamic support devices;
  6. Need for emergency surgery for any reason;
  7. Hypertrophic cardiomyopathy with obstruction;
  8. Severe left ventricular dysfunction with (LVEF) \< 20%;Severe right ventricular dysfunction;
  9. Active peptic ulcer or upper gastro-intestinal bleeding within the past 3 months;
  10. Known or to all anticoagulation/antiplatelet regimens, to nitinol, contrast media or other relevant elements.
  11. Congenital aortic valve stenosis or unicuspid aortic valve;
  12. Vascular diseases or anatomical condition preventing the device access;
  13. Active endocarditis or other active infections at the time of treatment;
  14. Participating in another trial and the primary endpoint is not achieved.
  15. Inability to comply with the clinical investigation follow-up or other requirements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (estimated)

Study arms

  • Experimental
    Single arm clinical investigation

    Subjects in experimental group will be implanted with the VitaFlow™ II Transcatheter Aortic Valve System

    Device: VitaFlow™ II Transcatheter Aortic Valve System

Interventions

  • DeviceVitaFlow™ II Transcatheter Aortic Valve System

    VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire

06

What researchers measure

Primary outcomes

  1. Rate of all-cause mortality at 12 months post implantation

    Rate of all-cause mortality including cardiovascular and non-cardiovascular death

    Time frame: 12 months post implantation

Secondary outcomes

  1. Valve function-mean prosthetic valve gradient

    Mean prosthetic valve gradient measured by transthoracic echocardiography (TTE)(in mmHg)

    Time frame: at 30 days, 6 months, and 1 year post implantation

  2. Valve function- effective orifice area

    Effective orifice area measured by transthoracic echocardiography (TTE)(in cm\^2)

    Time frame: at 30 days, 6 months, and 1 year post implantation

  3. Valve function- degree of prosthetic valve regurgitation

    Degree of prosthetic valve regurgitation including paravalvular leak and intravalvular regurgitation measured by transthoracic echocardiography (TTE)

    Time frame: at 30 days, 6 months, and 1 year post implantation

  4. Rate of safety events according to VARC2

    Rate of safety events according to VARC2 including all-cause mortality, myocardial infarction, stroke, bleeding, acute kidney injury, vascular complications, conduction disturbance and arrhythmias, and new permanent pacemaker implantation

    Time frame: at 30 days, 6 months, 1 year and annually up to 5 years post implantation

  5. Rate of other TAVI-related complications

    Rate of other TAVI-related complications including conversion to open surgery, unplanned use of cardiopulmonary bypass, coronary obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade, endocarditis, valve thrombosis, valve mal-positioning, and TAV-in-TAV

    Time frame: at 30 days, 6 months, 1 year and annually up to 5 years post implantation

  6. Rate of major adverse cardiac and cerebrovascular events(MACCE)

    Rate of MACCE including all-cause mortality, stroke, myocardial infarction, re-intervention, arrhythmias, and conduction disturbances

    Time frame: at 30 days, 6 months, 1 year and annually up to 5 years post implantation

  7. Rate of device success

    Rate of device success, assessed by death, the access, delivery, deployment and implantation of the device, prosthetic valve position and valve function

    Time frame: at immediate post implantation

  8. Rate of balloon pre-dilation success

    Rate of balloon pre-dilation success, assessed by the access, delivery, pre-dilation and retrieval of the balloon catheter

    Time frame: at immediate post implantation

  9. Rate of balloon post-dilation success

    Rate of balloon post-dilation success, assessed by the access, delivery, post-dilation and retrieval of the balloon catheter

    Time frame: at immediate post implantation

  10. Rate of procedure success

    Rate of procedure success, assessed by the device success and the peri-procedural complications

    Time frame: at immediate post implantation

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Jan 2022, 48 months after the start.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 48 months is above that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 4, 2020
StartActual
Jan 31, 2018
Primary completionEst.
Jan 31, 2022
CompletionEst.
Jan 31, 2027
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04414878
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Jan 31, 2018
Primary completion
Jan 31, 2022 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 4, 2020

Study contacts

Bi Jie
Contact
jbi@microport.com
(86)(21)38954600
Zhujun Cai, PhD
Contact
zjcai@microport.com
(86)(21)38954600

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion